BIIB
Price
$132.15
Change
-$0.50 (-0.38%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
19.45B
54 days until earnings call
GSK
Price
$39.53
Change
+$0.09 (+0.23%)
Updated
Aug 29, 04:01 PM (EDT)
Capitalization
80.35B
61 days until earnings call
Interact to see
Advertisement

BIIB vs GSK

Header iconBIIB vs GSK Comparison
Open Charts BIIB vs GSKBanner chart's image
Biogen
Price$132.15
Change-$0.50 (-0.38%)
Volume$20.76K
Capitalization19.45B
GSK
Price$39.53
Change+$0.09 (+0.23%)
Volume$2.31K
Capitalization80.35B
BIIB vs GSK Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. GSK commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and GSK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (BIIB: $132.65 vs. GSK: $39.44)
Brand notoriety: BIIB: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 113% vs. GSK: 99%
Market capitalization -- BIIB: $19.45B vs. GSK: $80.35B
BIIB [@Pharmaceuticals: Major] is valued at $19.45B. GSK’s [@Pharmaceuticals: Major] market capitalization is $80.35B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileGSK’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • GSK’s FA Score: 1 green, 4 red.
According to our system of comparison, GSK is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 6 bullish TA indicator(s).

  • BIIB’s TA Score: 4 bullish, 5 bearish.
  • GSK’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -4.65% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.60% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

GSK is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GSK($80.3B) has a higher market cap than BIIB($19.4B). GSK has higher P/E ratio than BIIB: GSK (17.69) vs BIIB (12.69). GSK YTD gains are higher at: 20.573 vs. BIIB (-13.255). GSK has higher annual earnings (EBITDA): 8.61B vs. BIIB (2.79B). GSK has more cash in the bank: 3.62B vs. BIIB (2.76B). BIIB has less debt than GSK: BIIB (6.6B) vs GSK (17.4B). GSK has higher revenues than BIIB: GSK (31.6B) vs BIIB (10B).
BIIBGSKBIIB / GSK
Capitalization19.4B80.3B24%
EBITDA2.79B8.61B32%
Gain YTD-13.25520.573-64%
P/E Ratio12.6917.6972%
Revenue10B31.6B32%
Total Cash2.76B3.62B76%
Total Debt6.6B17.4B38%
FUNDAMENTALS RATINGS
BIIB vs GSK: Fundamental Ratings
BIIB
GSK
OUTLOOK RATING
1..100
1623
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5953
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (89) in the Biotechnology industry. This means that GSK’s stock grew significantly faster than BIIB’s over the last 12 months.

GSK's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that GSK’s stock grew similarly to BIIB’s over the last 12 months.

GSK's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that GSK’s stock grew similarly to BIIB’s over the last 12 months.

GSK's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as BIIB (59) in the Biotechnology industry. This means that GSK’s stock grew similarly to BIIB’s over the last 12 months.

GSK's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that GSK’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBGSK
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
49%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
48%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
54%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 8 days ago
53%
Bullish Trend 3 days ago
58%
Declines
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 24 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
48%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BULZ201.634.90
+2.49%
MicroSectors™ Slct FANG Inn 3X Lvgd ETNs
BEGS34.510.07
+0.22%
Rareview 2X Bull Cryptoccy & Prc Mtl ETF
JULW38.030.07
+0.19%
AllianzIM US Large Cap Buffer20 Jul ETF
BUL53.080.08
+0.14%
Pacer US Cash Cows Growth ETF
BEEZ33.680.01
+0.04%
Honeytree U.S. Equity ETF

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-1.18%
NVS - GSK
67%
Closely correlated
-0.33%
AZN - GSK
63%
Loosely correlated
+0.08%
PFE - GSK
57%
Loosely correlated
-1.87%
SNY - GSK
55%
Loosely correlated
-0.34%
JNJ - GSK
49%
Loosely correlated
-0.76%
More